Related Experiment Video
Updated: Oct 2, 2025

Author Spotlight: Advantages of Pressure-Volume Loop Measurement Method in Cardiovascular Research
Published on: January 12, 2024
Gallic acid protects against isoproterenol-induced cardiotoxicity in rats
Dareuosh Shackebaei1,2, Mahvash Hesari1, Soudabeh Ramezani-Aliakbari1,3
1Medical Biology Research Center, Health Technology Institute, 48464Kermanshah University of Medical Sciences, Kermanshah, Iran.
Background:
Gallic acid (GA) is a polyphenolic agent with interesting pharmacological impacts on the cardiovascular system.
Objective:
The present study purposed to study the protective effects of GA at 25 and 50 mg/kg against isoproterenol (ISO)-induced cardiac damage in ischemia/reperfusion (I/R) in rats.
Methods:
Male Wistar rats were randomly assigned into six groups: Control, Control treated with GA at 25 mg/kg (GA25), Control treated with GA at 50 mg/kg (GA50), Hypertrophic rats induced by ISO (ISO), Hypertrophic rats treated with GA at 25 mg/kg (ISO+GA25), and Hypertrophic rats treated with GA at 50 mg/kg (ISO+GA50). Heart isolation was performed to induce a cardiac I/R injury model. Cardiac hemodynamic parameters were recorded. Serum Lactate Dehydrogenase (LDH) and Creatine Kinase-MB (CK-MB) and cardiac Superoxide dismutases (SOD) levels were evaluated. The gene expression of Sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) was assessed.
Results:
We found that GA at 50 mg/kg was significantly increased cardiac function at post I/R period in ISO-induced hypertrophic hearts. Moreover, it suppressed cardiac hypertrophy, the serum LDH and CK-MB levels in ISO injected rats. Administration of GA at 50 mg/kg was significantly increased SOD level and SERCA2a gene expression in the hypertrophic hearts.
Conclusion:
GA at 50 mg/kg could improve cardiac performance possibly by increasing antioxidant defense enzymes, reducing cell damage, and enhancing SERCA2a gene expression in hypertrophic heart induced by ISO in I/R injury conditions.
More Related Videos
Related Concept Videos
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
G-Protein Gated Ion Channels
Sensory...
GPCRs Regulate Adenylyl Cylase Activity
Cardiopulmonary Resuscitation IV: Pharmacological Management
Cardiomyopathy V: Interprofessional Care

